Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance

[en] Diffuse large B-cell lymphoma (DLBCL), the single largest category of lymphoma, is a clinically and biologically heterogeneous disease entity. Clinically, patients differ in their mode of presentation and respond variably to therapy. A combination of clinical parameters can be used to predict the patient's response to therapy and survival. The pathological variability of DLBCL is expressed in morphology, immunophenotype, cytogenetic and molecular genetic features. Numerous markers detectable by immunohistochemistry and linked to different aspects of tumour biology have been studied in DLBCL, including lineage-associated and immune markers, proliferation and apoptosis markers, cell adhesion molecules, and more recently stage-specific markers of B-cell differentiation. This review summarizes these studies in regard to their clinical significance and in the light of recent advances in our understanding of the molecular pathology and histogenesis of DLBCL.

Disciplines :

Oncology

Author, co-author :

de Leval, Laurence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Harris, N. L.

Language :

English

Title :

Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance

Publication date :

December 2003

Journal title :

Histopathology

ISSN :

0309-0167

eISSN :

1365-2559

Publisher :

Blackwell Publishing Ltd, Oxford, United Kingdom

Volume :

Issue :

Pages :

509-528

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 December 2020

Statistics

Number of views

63 (2 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Jaffe E, Harris N, Stein H, Vardiman J. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
Shipp M, Harris N, Mauch P. The non-Hodgkin's lymphomas. In De Vita VT, Hellman S, Rosenberg S eds. Principles and practice of oncology. Philadelphia: Lippincott, 1997.
The International non-Hodgkin's lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993: 329; 987-994.
Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994: 84; 1361-1392.
Engelhard M, Brittinger G, Huhn D et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997: 89; 2291-2297.
Baars J, de Jong D, Willemse E et al. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification. Br. J. Cancer 1999: 79; 1770-1776.
Fernandez de Sevilla S, Romagosa V, Domingo-Claros A et al. Diffuse large B-cell lymhpoma: is morphologic subdivision useful in clinical management? Eur. J. Haematol. 1998: 60; 202-208.
Diebold J, Anderson J, Armitage J et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk. Lymphoma 2002: 43; 97-104.
Kuppers R., Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N. Engl. J. Med. 1999: 341; 1520-1529.
Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000: 95; 1797-1803.
Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000: 403; 503-511.
Rosenwald A, Wright G, Chan W et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002: 25; 1937-1947.
Knowles D. Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms. In Knowles D ed. Neoplastic hematopathology. Philadelphia: Lippincott Williams, & Winkins, 2001: 93-226.
Chang K, Arber D, Weiss L. CD20: a review. Appl. Immunohistochem. 1996: 4; 1-14.
Mason D, Cordell J, Brown M et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995: 86; 1453-1459.
Norton A, Isaacson P. Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues. J. Clin. Pathol. 1987: 40; 1405-1412.
Quintanilla-Martinez L, Preffer F, Rubin D, Ferry J, Harris N. CD20+ T cell lymphoma: neoplastic transformation of a normal T-cell subset. Am. J. Clin. Pathol. 1994: 102; 483-489.
Blakolmer K, Vesely M, Kummer A, Jurecka W, Mannhalter C, Chott A. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T-(NK/T-) cell lymphomas. Mod. Pathol. 2000: 13; 766-772.
Mohrmann R & Arber D. CD20-positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin's disease and review of the literature. Mod. Pathol. 2000: 13; 1244-1252.
Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe E. Peripheral T-cell lymhpoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod. Pathol. 2001: 14; 105-110.
Torlakovic E, Torlakovic G, Nguyen P, Brunning R, Delabie J. The value of anti-Pax-5 immunostaining in routinely fixed and paraffin-embedded sections. A novel pan pre-B and B-cell marker. Am. J. Surg. Pathol. 2002: 26; 1143-1150.
Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin. Oncol. 2002: 29 (1S2); 30-35.
Davis T, Czerwinski K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 1999: 5; 611-615.
Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 1986: 10; 379-390.
Lamarre L, Jacobson J, Aisenberg A, Harris N. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am. J. Surg. Pathol. 1989: 13; 730-739.
Horning S, Doggett R, Warnke R, Dorfman R, Cox R, Levy R. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood 1984: 63; 1209-1215.
Kwak L, Campbell M, Czerwinski D, Hart S, Miller R, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992: 327; 1209-1215.
Möller P, Herrman B, Moldenhauer G, Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int. J. Cancer 1987: 40; 32-39.
Momburg F, Herrmann B, Moldenhauer G, Möller P. B-cell lymphomas of high-grade malignancy frequently lack HLA-DR-DP and -DQ antigens and associated invariant chain. Int. J. Cancer 1987: 40; 598-603.
Miller T, Lippman S, Spier C, Slymen D, Grogan T. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J. Clin. Invest. 1988: 82; 370-372.
Spier C, Grogan T, Lippman S, Slymen D, Rybski J, Miller T. The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. Am. J. Pathol. 1988: 133; 118-126.
Slymen D, Miller T, Lippman S et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J. Clin. Oncol. 1990: 8; 986-993.
Riemersma S, Jordanova E, Schop R et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000: 96; 3569-3573.
Lippman S, Spier C, Miller T, Slymen D, Rybski J, Grogan T. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod. Pathol. 1990: 3; 361-367.
Stopeck A, Gessner A, Miller T et al. Loss of B7.2 (CD86) and intercellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin. Cancer Res. 2000: 6; 3904-3909.
Ansell S, Stenson M, Habermann T, Jelinek D, Witzig T. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J. Clin. Oncol. 2001: 19; 720-726.
Xu Y, Kroft S, McKenna R, Aquino D. Prognostic significance of tumour-infiltrating lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparametric flow cytometry study. Br. J. Haematol. 2000: 112; 945-949.
Kipps T. The CD5 B cell. Adv. Immunol. 1989: 47; 117-185.
Burns B, Warnke R, Doggett R, Rouse R. Expression of a T-cell antigen (Leu 1) by B-cell lymphomas. Am. J. Pathol. 1983: 113; 165-171.
Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002: 99; 815-821.
Kroft S, Howard M, Picker L, Ansari M, Aquino D, McKenna R. De novo CD5+ diffuse large B-cell lymphomas - a heterogeneous group containing an unusual form of splenic lymphoma. Am. J. Clin. Pathol. 2000: 114; 523-533.
Harada S, Suzuki R, Uehira K et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5-with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999: 13; 1441-1447.
Matolcsy A, Chadburn A, Knowles D. De novo CD5+ and Richter's syndrome-associated diffuse large B-cell lymphomas are genotypically distinct. Am. J. Pathol. 1995: 147; 207-216.
Yamaguchi M, Ohno T, Oka K. De novo CD5+ diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br. J. Haematol. 1999: 5; 1113-1139.
Katzenberger T, Lohr A, Schwarz S et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003: 101; 699-702.
Lai R, Weiss L, Chang K, Arber D. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am. J. Clin. Pathol. 1999: 111; 488-494.
Gelb A, Rouse R, Dorfman R, Warnke R. Detection of immunophenotypic abnormalities in paraffin-embedded B-lineage non-Hodgkin's lymphomas. Am. J. Clin. Pathol. 1994: 102; 825-834.
Gerdes J, Lemke H, Baisch H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984: 133; 1710-1715.
Hall P, Richards M, Gregory W, d'Ardenne A, Lister T, Stansfeld A. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J. Pathol. 1988: 154; 223-235.
Grogan T, Lippman S, Spier C. Independent prognostic significance of the nuclear proliferation antigen in diffuse large-cell lymphoma as determined by the monoclonal antibody Ki-67. Blood 1988: 71; 1157-1160.
Miller T, Grogan T, Dahlberg S et al. Prognostic significance of the KI-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994: 83; 1460-1466.
Tominaga K, Yamaguchi Y, Nozawa Y, Abe M, Wakasa H. Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67. Hematol. Oncol. 1992: 10; 163-169.
Sanchez E, Chacon I, Munoz E et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J. Clin. Oncol. 1998: 16; 1931-1939.
Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1991: 351; 453-456.
Gascoyne R. Pathologic prognostic factors in aggressive non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North Am. 1997: 11; 847-862.
Ichikawa A, Kinoshia T, Watanabe T et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl. J. Med. 1997: 337; 529-534.
Leroy K, Haioun C, Lepage E et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphoma. Ann. Oncol. 2002: 13; 1108-1115.
Wilson W, Teruya-Feldstein J, Fest T. Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997: 89; 601-609.
Piris M, Pezella F, Martinez-Montero J et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br. J. Cancer 1994: 69; 337-341.
Zhang A, Ohshima K, Sato K et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol. Int. 1999: 49; 1043-1052.
Kramer M, Hermans J, Parker J et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J. Clin. Oncol. 1996: 14; 2131-2138.
Barrans S, Carter I, Owen R, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002: 99; 1136-1143.
Chilosi M, Doglioni C, Magalini A et al. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996: 88; 4012-4020.
Moller M, Gerdes A, Skjodt K, Mortensen L, Pedersen N. Disrupted p53 function as predictor of treatment failure and poor prognosis in B-and T-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 1999: 5; 1085-1091.
Pagnano K, Vassallo J, Lorand-Metze I, Costa F, Saad S. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am. J. Hematol. 2001: 67; 84-92.
Chiarle R, Fan Y, Piva R et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlate with p27 expression and defines cells in S phase. Am. J. Pathol. 2002: 160; 1457-1466.
Lim M, Adamson A, Lin Z et al. Expression of Skp2, a p27Kip1 ubiquitin ligase, in malignant lymphoma: correlation with p27Kip1 and proliferation index. Blood 2002: 100; 2950-2956.
Saez A, Sanchez E, Sanchez-Beato M et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br. J. Cancer 1999: 80; 1427-1434.
Sanchez-Beato M, Camacho F, Martinez-Montero J et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocallzation in tumor cells. Blood 1999: 94; 765-772.
Filipits M, Jaeger U, Pohl G et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin. Cancer Res. 2002: 8; 729-733.
Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985: 228; 1440-1443.
Jacobson J, Wilkes B, Kwaiatkowski D, Medeiros L, Aisenberg A, Harris N. Bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer 1993: 72; 231-236.
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990: 348; 334-336.
Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14:18 chromosomal translocation. Am. J. Pathol. 1990: 137; 225-232.
Villuendas R, Piris M, Orradre J, Mollejo M, Rodriguez R, Morente M. Different bcl-2 protein expression in high-grade B-cell lymphomas derived from lymph nodes or mucosa-associated lymphoid tissue. Am. J. Pathol. 1991: 139; 989-993.
Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum. Pathol. 1999: 30; 803-808.
Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of bcl2 overexpression in diffuse large B-cell lymphoma. Leukemia Lymphoma 2001: 42; 1089-1098.
Rao P, Houldsworth J, Dyomina K. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998: 92; 234-240.
Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997: 90; 1168-1174.
Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996: 88; 1046-1051.
Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997: 90; 244-251.
Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996: 87; 265-272.
Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003: 101; 78-84.
Oltvai Z, Milliman C, Korsmeyer S. Bcl-2 heterodimerizes in vitro with a conserved homolog, Bax, that accelerated programmed cell death. Cell 1993: 74; 609-619.
Gascoyne R, Krajewska M, Krajewski S, Connors J, Reed J. Prognostic significance of bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997: 90; 3173-3178.
Adida C, Haioun C, Gaulard P et al. Prognostic significance of survivin expression in diffuse large B-cell lymphoma. Blood 2000: 96; 1921-1925.
Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies to Pgp-1/CD44 block lymphohemopoiesis in long-term bone marrow cultures. J. Exp. Med. 1990: 171; 477-488.
Jalkanen ST, Bargatze RF, Herron LR, Butcher EC. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur. J. Immunol. 1986: 16; 1195-1202.
Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv. Immunol. 1993: 54; 271-335.
Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJ. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989: 73; 885-888.
Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991: 65; 13-24.
Salles G, Zain M, Boussiotis V, Shipp M. Alternatively spliced CD44 transcripts in diffuse large cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993: 82; 3539-3547.
Yakushijin Y, Steckel J, Kharbanda S et al. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. Blood 1998: 91; 4282-4291.
Salles G, Zain M, Jiang W, Boussiotis V, Shipp M. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: CD44 variant: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993: 82; 3539-3547.
Drillenburg P, Pals S. Cell adhesion molecules in lymphoma dissemination. Blood 2000: 95; 1900-1910.
Horst E, Meijer CJ, Radaskiewicz T et al. Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. Leukemia 1990: 4; 383-389.
Drillenburg P, Wielenga VJ, Kramer MH et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 1999: 13; 1448-1455.
Stauder R, Eisterer W, Thaler J, Gunther U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995: 85; 2885-2899.
Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod. Pathol. 1999: 12; 546-552.
Dalla-Favera R, Ye BH, Lo Coco F et al. Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann. Oncol. 1994: 5; 55-60.
Ye BH, Chaganti S, Chang CC et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995: 14; 6209-6217.
Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc. Natl Acad. Sci. USA 1996: 93; 6947-6952.
Deweindt C, Albagli O, Bernardin F et al. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain. Cell Growth Differ. 1995: 6; 1495-1503.
Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene 1996: 12; 2331-2342.
Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997: 276; 589-592.
Ye BH, Cattoretti G, Shen Q et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 1997: 16; 161-170.
Cattoretti G, Chang CC, Cechova K et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995: 86; 45-53.
Flenghi L, Ye BH, Fizzotti M et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am. J. Pathol. 1995: 147; 405-411.
Flenghi L, Bigerna B, Fizzotti M et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am. J. Pathol. 1996: 148; 1543-1555.
Shaffer A, Yu X, He Y, Boldrick J, Chan E, Staudt L. BCL-6 represses genes that function in lymphocyte differentiation, inflammation and cell cycle control. Immunity 2000: 13; 199-212.
Dent A, Vasanwala F, Toney L. Regulation of gene expression by the proto-oncogene BCL-6. Crit. Rev. Oncol. Hematol. 2002: 41; 1-9.
Onizuka T, Moriyama M, Yamochi T et al. BCL-6 gene product, a 92-to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood 1995: 86; 28-37.
Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann. Oncol. 1997: 8; 101-104.
Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am. J. Clin. Pathol. 1999: 112; 101-107.
Dogan A, Bagdi E, Munson P, Isaacson P. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am. J. Surg. Pathol. 2000: 24; 846-852.
de Leval L, Harris N, Longtine J, Ferry J, Duncan L. Cutaneous B-cell lymphomas of follicular and marginal zone types. Use of bcl-6, CD10, bcl-2 and CD21 in differential diagnosis and classification. Am. J. Surg. Pathol. 2001: 25; 732-741.
Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of lymphomas: a work in progress. Ann. Oncol. 1998: 9; S25-30.
de Leval L, Shipp M, Neuberg D, Ferry J, Harris N. Nodal diffuse large B-cell lymphomas (DLB-CLs) are more likely to be derived from geminal center B-cells than extranodal DLB-CLs. Blood 1999: 94; 521a.
de Leval L, Ferry J, Falini B, Shipp M, Harris N. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma. Evidence for derivation from germinal center B cells? Am. J. Surg. Pathol. 2001: 25; 1277-1282.
de Leval L, Braaten K, Ancukiewicz M et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am. J. Surg. Pathol. 2003: 27; 1269-1277.
Braaten K, Betensky R, de Leval L et al. Bcl-6 expression predicts improved survival in patients with primary central nervous sytem lymphoma. Clin. Cancer Res. 2003: 9; 1063-1069.
Ye BH, Lista F, Lo Coco F et al. Alterations of a zinc finger-encoding gene. BCL-6, in diffuse large-cell lymphoma. Science 1993: 262; 747-750.
Lo Coco F, Ye BH, Lista F et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994: 83; 1757-1759.
Butler M, Lida S, Capello D et al. Alternative translocation breakpoint cluster region 5′ to BCL6 in B-cell non-Hodgkin's lymphoma. Cancer Res. 2002: 62; 4089-4094.
Capello D, Vitolo U, Pasqualucci L et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000: 95; 651-659.
Artiga M, Saez A, Romero C et al. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am. J. Pathol. 2002: 160; 1371-1380.
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti R, Dalla-Favera R. Mutations of the BCL6 protooncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003: 101; 2914-2923.
Bastard C, Deweindt C, Kerckaert JP et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994: 83; 2423-2427.
Pescarmona E, De Sanctis V, Pistilli A et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J. Pathol. 1997: 183; 281-286.
Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998: 92; 3152-3162.
Jerkeman M, Aman P, Cavallin-Stahl E et al. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B cell lymphoma - a Nordic Lymphoma Group study. Int. J. Oncol. 2002: 20; 161-165.
Barrans S, O'Connor S, Evans P et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br. J. Haematol. 2002: 117; 322-332.
Ueda C, Akasaka T, Ohno H. Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications. Leuk. Lymphoma 2002: 43; 1375-1381.
Ueda C, Uchiyama T, Ohno H. Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high-versus low-level expression of BCL6 mRNA. Blood 2002: 99; 2624-2625.
Lossos I, Jones C, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001: 98; 945-951.
Bai M, Agnantis N, Skyrlas A et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphoma. Mod. Pathol. 2003: 16; 471-480.
Shipp MA, Vijayaraghavan J, Schmidt EV et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ('enkephalinase'): direct evidence by cDNA transfection analysis. Proc. Natl Acad. Sci. USA 1989: 86; 297-301.
LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10) - emancipation from a functional enigma. Blood 1989: 73; 625-635.
McIntosh GG, Lodge AJ, Watson P et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am. J. Pathol. 1999: 154; 77-82.
Kaufmann O, Flath B, Spath-Schwalbe E, Possinger K, Dietel M. Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am. J. Clin. Pathol. 1999: 111; 117-122.
Watson P, Wood K, Lodge A et al. Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in diagnosis of small B-cell lymphoma. Histopathology 2000: 36; 145-150.
King B, Chen C, Locker J et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphoma. Mod. Pathol. 2000: 13; 1219-1231.
Ohshima K, Kawasaki C, Muta K et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001: 39; 156-162.
Fabiani B, Delmer A, Lepage E et al. Prognostic significance and morphological features of diffuse large B-cell lymphomas expressing CD10. J. Clin. Pathol. 2002: 55S1; A14.
Uherova P, Ross C, Schnitzer B, Singleton T, Finn W. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphomas. Am. J. Clin. Pathol. 2001: 115; 582-588.
Xu Y, McKenna R, Molberg K, Kroft S. Clinicopathological analysis of CD10+ and CD10-diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am. J. Clin. Pathol. 2001: 116; 183-190.
Go J, Yang W, Ree H. CD10 expression in primary intestinal large B-cell lymphomas. Arch. Pathol. Lab. Med. 2002: 126; 956-960.
Xu Y, McKenna R, Kroft S. Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-cell lymphomas. Mod. Pathol. 2002: 15; 413-419.
Huang J, Sanger W, Greiner T et al. The t(14:18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002: 99; 2285-2290.
McCluggage W, Catherwood M, Alexander H, McBride H, Smith M, Morris T. Immunohistochemical expression of CD10 and t(14:18) chromosomal translocation may be indicators of follicle center origin in nodal diffuse large B-cell lymphoma. Histopathology 2002: 41; 414-420.
Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003: epub ahead of print.
de Jong D, Glas A, Boerrigter L et al. Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood 2003: 102; 324-327.
Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells and activated T cells. Blood 2000: 95; 2084-2092.
Tsuboi K, Iida S, Inagaki H et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000: 14; 449-456.
Natkunam Y, Warnke R, Montgomery K, Falini B, van de Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod. Pathol. 2001: 14; 686-694.
Banham AH, Turley H, Pulford K, Gatter K, Mason DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J. Clin. Pathol. 1997: 50; 485-489.
Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma celldifferentiation in routine sections. J. Clin. Pathol. 1994: 47; 418-422.
Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989: 1; 27-35.
Carbone A, Gaidano G, Gloghini A et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998: 91; 747-755.
Carbone A, Gloghini A, Larocca L et al. Expression profile of MUM1/IRF4, BCL-6 and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001: 97; 744-751.
Delecluse H, Anagnostopoulos I, Dallenbach F et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997: 89; 1413-1420.
Carbone A, Gaidano G, Gloghini A, Ferlito A, Rinaldo A, Stein H. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann. Otol. Rhinol. Laryngol. 1999: 108; 95-99.